Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Organ damage Dx and arterial closure tech capture IMDA's attention

This article was originally published in Clinica

Executive Summary

Organ damage diagnostics and arterial closure devices have helped their developers gain the accolade of most promising companies in the 2009 industry excellence awards of the Irish Medical Device Association (IMDA). Dublin-based Argutus Medical, which won the title of "emerging company of the year", develops and commercialises laboratory test kits for identifying early signs of injury to the kidney, liver and pancreas. Runner-up Vasorum, also based in Dublin, is the developer of the AstraPlug, a resorbable implant used to close puncture sites in arteries. The firm claims that the global arterial closure market is expected to surpass $1bn in 2010. It estimates that 8.6 million catheter-based procedures were performed in the US and EU in 2006, and that this number is expected to exceed 10 million next year. Gastroenterlogy was also featured among the winners, with Galway-based Crospon named overall medtech company of the year. Crospon is the developer of EndoFLIP, a catheter-based imaging system for diagnosing gastro-oesophageal reflux disease (GERD).

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts